Feliza Mirasol

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Applying modeling methods in preclinical studies can be a powerful tool for generating data and shortening development timelines.

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Testing cleanroom garments while in use and during daily cleanroom operations is vital for contamination control.

A rise in investments and funding into regenerative medicines projects has helped to advance a rich clinical pipeline.

The use of bioengineering offers practical tools for the evolution of host cells.

Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.